Literature DB >> 11314776

Clinical significance of neurobiochemical profiles in the lumbar cerebrospinal fluid of Alzheimer's disease patients.

N Rösler1, I Wichart, K A Jellinger.   

Abstract

Immunoreactivities of total apolipoprotein E (ApoE-IR), amyloid beta peptide(1-42) (Abeta42-IR), interleukin-6 (IL-6-IR), substance P (SPIR) and total tau protein (TTIR) were measured in lumbar cerebrospinal fluid samples of patients with Alzheimer's disease (AD), non-Alzheimer's dementias (NAD), neurological disorders without cognitive impairment (OND) and controls without central nervous system disease using sensitive and specific enzyme immunoassay methods. TTIR was highly significantly increased (P < 0,001) and Abeta42-IR was significantly decreased (P < 0,001 vs. OND/CO, P < 0,03 vs. NAD) in the AD cohort compared with the other diagnostic groups. Significant increases in AD were also found for ApoE-IR (P < 0,001) and IL-6 (P < 0,03), but there was a considerable overlap between groups. In the total AD cohort, SPIR was not significantly changed, but AD patients with late disease onset (>65 years) showed significantly higher values than both early onset patients (<65 years) and controls (P < 0,05). Discriminant function analysis showed that Abeta42-IR (cut-off value 375pg/ml) and TTIR (cut-off value 440 pg/ml) levels contributed most to the group classification of patients. At 85% sensitivity for AD and 100% specificity for controls, the combined evaluation of Abeta42-IR and TTIR in this cross-sectional study resulted in a graph separating AD from non-AD patients with increased specificity of 91% and 75% for AD versus OND and NAD, respectively.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11314776     DOI: 10.1007/s007020170091

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  81 in total

1.  Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

Authors:  N Andreasen; C Hesse; P Davidsson; L Minthon; A Wallin; B Winblad; H Vanderstichele; E Vanmechelen; K Blennow
Journal:  Arch Neurol       Date:  1999-06

2.  Cerebrospinal fluid apolipoprotein E (apoE) levels in Alzheimer's disease patients are increased at follow up and show a correlation with levels of tau protein.

Authors:  M Lindh; M Blomberg; M Jensen; H Basun; L Lannfelt; B Engvall; H Scharnagel; W März; L O Wahlund; R F Cowburn
Journal:  Neurosci Lett       Date:  1997-06-27       Impact factor: 3.046

3.  Increased levels of tau protein in cerebrospinal fluid of patients with Alzheimer's disease--correlation with degree of cognitive impairment.

Authors:  C Hock; S Golombowski; W Naser; F Müller-Spahn
Journal:  Ann Neurol       Date:  1995-03       Impact factor: 10.422

4.  Central nervous system IgG synthesis rates in Alzheimer disease: possible differences in early-onset and late-onset subgroups.

Authors:  G W Small; M Rosenthal; W W Tourtellotte
Journal:  Alzheimer Dis Assoc Disord       Date:  1994       Impact factor: 2.703

5.  Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

Authors:  D Blum-Degen; T Müller; W Kuhn; M Gerlach; H Przuntek; P Riederer
Journal:  Neurosci Lett       Date:  1995-12-29       Impact factor: 3.046

6.  Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices.

Authors:  J Bauer; S Strauss; U Schreiter-Gasser; U Ganter; P Schlegel; I Witt; B Yolk; M Berger
Journal:  FEBS Lett       Date:  1991-07-08       Impact factor: 4.124

7.  Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid.

Authors:  T Wisniewski; A Golabek; E Matsubara; J Ghiso; B Frangione
Journal:  Biochem Biophys Res Commun       Date:  1993-04-30       Impact factor: 3.575

Review 8.  Biological markers for the diagnosis of Alzheimer's disease.

Authors:  C Bancher; K Jellinger; I Wichart
Journal:  J Neural Transm Suppl       Date:  1998

9.  Cerebrospinal fluid apolipoprotein E is reduced in Alzheimer's disease.

Authors:  K Blennow; C Hesse; P Fredman
Journal:  Neuroreport       Date:  1994-12-20       Impact factor: 1.837

10.  Concentrations of amyloid-beta protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease.

Authors:  W A van Gool; D B Schenk; P A Bolhuis
Journal:  Neurosci Lett       Date:  1994-05-19       Impact factor: 3.046

View more
  13 in total

1.  Substance P and Antagonists of the Neurokinin-1 Receptor in Neuroinflammation Associated with Infectious and Neurodegenerative Diseases of the Central Nervous System.

Authors:  Alejandra N Martinez; Mario T Philipp
Journal:  J Neurol Neuromedicine       Date:  2016

2.  CSF biomarkers in different phenotypes of Parkinson disease.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2011-11-08       Impact factor: 3.575

Review 3.  Cerebrospinal fluid protein biomarkers for Alzheimer's disease.

Authors:  Kaj Blennow
Journal:  NeuroRx       Date:  2004-04

Review 4.  Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders.

Authors:  Huan Cai; Wei-na Cong; Sunggoan Ji; Sarah Rothman; Stuart Maudsley; Bronwen Martin
Journal:  Curr Alzheimer Res       Date:  2012-01       Impact factor: 3.498

Review 5.  The mammalian tachykinin ligand-receptor system: an emerging target for central neurological disorders.

Authors:  Nick Pantaleo; Wayne Chadwick; Sung-Soo Park; Liyun Wang; Yu Zhou; Bronwen Martin; Stuart Maudsley
Journal:  CNS Neurol Disord Drug Targets       Date:  2010-11       Impact factor: 4.388

Review 6.  Biomarkers of Alzheimer's disease.

Authors:  Rebecca Craig-Schapiro; Anne M Fagan; David M Holtzman
Journal:  Neurobiol Dis       Date:  2008-10-28       Impact factor: 5.996

Review 7.  Cerebrospinal fluid biomarkers of Alzheimer's disease.

Authors:  Xiaojing Sui; Jianjun Liu; Xifei Yang
Journal:  Neurosci Bull       Date:  2014-04-15       Impact factor: 5.203

Review 8.  Cerebrospinal fluid biomarkers of Alzheimer's disease in healthy elderly.

Authors:  Catherine Randall; Lisa Mosconi; Mony de Leon; Lidia Glodzik
Journal:  Front Biosci (Landmark Ed)       Date:  2013-06-01

9.  Age-related mild cognitive deficit: a ready-to-use concept?

Authors:  Christian Gilles
Journal:  Dialogues Clin Neurosci       Date:  2003-03       Impact factor: 5.986

10.  Plasma and cerebrospinal fluid ABeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting.

Authors:  Michelle Kokkinou; Lucy C Beishon; Nadja Smailagic; Anna H Noel-Storr; Chris Hyde; Obioha Ukoumunne; Rosemary E Worrall; Anja Hayen; Meera Desai; Abhishekh Hulegar Ashok; Eleanor J Paul; Aikaterini Georgopoulou; Tiziana Casoli; Terry J Quinn; Craig W Ritchie
Journal:  Cochrane Database Syst Rev       Date:  2021-02-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.